September 29, 2009 – Boston Scientific Corp. Sept. 25 announced two-year follow-up data from the HORIZONS-AMI trial, is designed to determine the safety and efficacy of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients experiencing an acute myocardial infarction (AMI).

September 29, 2009 – The United States Court of Appeals for the Federal Circuit last week affirmed the previous ruling of the United States District Court for the Northern District of California that Cook Incorporated does not infringe on Edwards’ patents for endovascular devices to treat aneurysms, Cook officials said.

September 28, 2009 – New data from the phase III PLATO study showed that ticagrelor (BRILINTA) provided 16 percent reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02 vs. 10.65 percent) in acute coronary syndromes patients undergoing planned invasive treatment of either PCI or CABG.

September 28, 2009 – Data supporting the long-term safety and effectiveness of renal sympathetic denervation (RDN) using radio-frequency ablation in treating patients with chronic hypertension were presented Sept. 25 at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

September 28, 2009 - GE Healthcare and Biosense Webster Inc. announced new versions of the Vivid i and Vivid q cardiovascular ultrasound systems, with support for two new intracardiac echo (ICE) catheters.

September 23, 2009 - After offering an amendment to close the in-office ancillary services exception for advanced medical imaging under the Stark law during the House Energy and Commerce Committee’s continued markup of H.R. 3200, America’s Affordable Health Choices Act of 2009, Rep. Anthony Weiner (D-NY) and Rep. Bruce Braley (D-IA) withdrew the offer.

September 23, 2009 – Abiomed Inc. announced new clinical data from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI).